Leerink on Friday raised the firm’s price target on ARS Pharmaceuticals to $20 from $19 and keeps an Outperform rating on the shares. The firm believes the FDA approval of ARS’ neffy in adults and pediatric patients with type 1 allergy was a positive surprise for investors that came months ahead of the FDA action date. The firm says the language in neffy’s FDA label appears straightforward with no major surprises on safety or administration language.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- Aquestive Therapeutics price target raised to $15 from $13 at Oppenheimer
- ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
- ARS Pharmaceuticals receives FDA approval of neffy
- ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
- ARS Pharmaceuticals reports Q2 EPS (13c), consensus (12c)